Retrospective Analysis With Propensity Score Matching of Peripheral T-Cell Lymphoma Treated Frontline With Brentuximab Vedotin and Chemotherapy

BACKGROUND: Since Food and Drug Administration approval of brentuximab vedotin in combination with cyclophosphamide, doxorubicin, and prednisone (A + CHP) as initial therapy for previously untreated CD30-expressing peripheral T-cell lymphoma (PTCL), there has been limited research on real-world pati...

Descripción completa

Detalles Bibliográficos
Autores principales: Burke, John M, Liu, Nicholas, Yu, Kristina S, Fanale, Michelle A, Surinach, Andy, Flores, Carlos, Lisano, Julie, Phillips, Tycel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Hematologic Malignancies
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10243782/
https://www.ncbi.nlm.nih.gov/pubmed/36971492
http://dx.doi.org/10.1093/oncolo/oyad068

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10243782/
https://www.ncbi.nlm.nih.gov/pubmed/36971492
http://dx.doi.org/10.1093/oncolo/oyad068

Ejemplares similares